Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091908 | 0.85 | L3MBTL1 (0.47) | ERCC5CREBBPALDH1A1HDAC1L3MBTL1 | |
| SCHEMBL3092873 | 0.80 | HPGD (0.49) | SLC16A3SLC16A1ALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL13153133 | 0.80 | CREBBP (0.50) | ERCC5CREBBPKDM4CALDH1A1KDM5B | |
| SCHEMBL3080718 | 0.80 | ALDH1A1 (0.44) | ERCC5CREBBPKDM4CKDM4EALDH1A1 | |
| SCHEMBL3096925 | 0.78 | TSHR (0.41) | KDM4EALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL15014107 | 0.78 | CREBBP (0.53) | ERCC5CREBBPKDM4CKDM4EALDH1A1 | |
| SCHEMBL15310228 | 0.78 | HSD17B10 (0.49) | KDM4EALDH1A1L3MBTL1NPSR1SMN1; SMN2 | |
| SCHEMBL3089049 | 0.77 | LMNA (0.50) | CREBBPKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3097121 | 0.77 | ALDH1A1 (0.50) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3470605 | 0.77 | ERCC5 (0.50) | ERCC5CREBBPKDM4CKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ERCC5 4812/4885CREBBP 2134/4885KDM4C 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.